Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant versus sequential infant vaccination with DTaP-IPV-HB-PRP-T and 4CMenB in Italy
2019-002585-12Phase 4Completed
- Sponsor
- Sanofi
- Start
- Aug 2020
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of hexaxim and Multicomponent meningococcal B vaccine in hepatitis B (HBV), Haemophilus influenzae type b disease (Hib), Meningococcal B infection and 4 more (2 arms), sponsored by Sanofi. Primary endpoint: Anti-HBsAg seroprotection rate. Started Aug 2020; status: completed.
02
Drugs
hexaximMulticomponent meningococcal B vaccine
03
Conditions
hepatitis B (HBV)Haemophilus influenzae type b disease (Hib)Meningococcal B infectiondiphtheriaTetanus
Beyond the preview
Go deeper on 2019-002585-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002585-12.